IBRX290119C00002000
IBRX Jan 19 2029 2.00 Call
optionOPRA
InactiveSep 21, 2026
6.70USD+1.824%(+0.12)2Vol16OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
2
Expiration
Jan 19, 2029
DTE
822d
Moneyness
ITM
Intrinsic
$6.48
IBRX 2 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 20, 2026 | 31d | $7.67 | +43.36% | 20 | 21 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $8.47 | +12.93% | 20 | 1,489 |
| Mar 19, 2027 | 150d | $5.35 | +0.00% | 210 | 210 |
| Apr 16, 2027 | 178d | $8.40 | +0.00% | 20 | 20 |
| May 21, 2027 | 213d | $7.70 | +0.00% | 1 | 0 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | — | — | 0 | 0 |
| Jan 21, 2028 | 458d | $7.90 | -10.63% | 4 | 5,401 |
| Mar 17, 2028 | 514d | $8.00 | +33.33% | 5 | 13 |
| Jan 19, 2029 | 822d | $6.70 | +1.82% | 2 | 16 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.